OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDY Palak J. Trivedi; Cynthia Levy; Kris V. Kowdley; Stuart C. Gordon; Christopher L. Bowlus; Maria Carlota Londoño Hurtado; Gideon M. Hirschfield; Aliya F. Gulamhusien; Eric J. Lawitz; Alejandra Villamil; Alma Ladron de Guevara Cetina; Marlyn J. Mayo; Ziad H. Younes; Oren Shibolet; Kidist K. Yimam; Daniel S. Pratt; Jeong Heo; Ulrike Morgera; Pietro Andreone; Andreas E. Kremer; Christophe Corpechot; Aparna Goel; Adam Peyton; Hany Elbeshbeshy; Daria B. Crittenden; Carrie Heusner; Sarah Proehl; Shuqiong Zhou; Charles A. McWherter;

EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS PREVIOUSLY TREATED WITH FIBRATES OR OBETICHOLIC ACID Alejandra M. Villamil; Daniel Pratt; Andreas E. Kremer; Vincenza Calvaruso; Elena Gómez Dominguez; Xin Qi; Sarah Proehl; William T. Barchuk; Timothy R. Watkins; Stuart C. Gordon;

Neurofilament light chain but not glial fibrillary acidic protein is a potential biomarker of overt hepatic encephalopathy in patients with cirrhosis Koos de Wit; Diederick J. van Doorn; Bregje Mol; Lonneke A. van Vught; Frederik Nevens; Ulrich Beuers; Cyriel Y. Ponsioen; Charlotte E. Teunissen; R. Bart Takkenberg;